Article

Glaucoma 360? draws experts from every angle

Advocates of glaucoma research and education are banding together to present Glaucoma 360?, three days of activities all geared toward increasing awareness of research, treating patients, and finding a cure for the nation's second-leading cause of preventable blindness.

Glaucoma 360° will be co-chaired by Adrienne Graves, PhD, and Andrew Iwach, MD, and will be held at San Francisco's historic Palace Hotel.

Glaucoma 360° combines the Glaucoma Research Foundation (GRF) annual gala with two meetings focused on glaucoma. The first, the "New Horizons Forum," brings together early-stage glaucoma companies, researchers, venture capitalists, industry executives, and FDA panelists to promote the kind of collaboration and understanding necessary for new product development.

By combining these three events, Glaucoma 360° will offer "a full-compass view" of "the cure, the catalysts, and the care" of glaucoma.

"I call it 'Glaucomapalooza,' " Dr. Graves said with a laugh.

All of the Glaucoma 360° events will benefit the GRF, which has spent $30 million since its 1978 inception to support researchers working to clarify the causes behind glaucoma and how the disease might best be treated or cured.

At the same time, organizers wanted to help small companies looking for assistance in navigating the murky waters of venture capital support, corporate buy-in, and regulatory approval. Drs. Graves and Iwach said they had admired the way Emmett Cunningham, MD, PhD, MPH, had brought together all of those segments for his popular "Ophthalmology Innovation Summit," and the GRF board wanted to build on that concept with a focus on glaucoma. Dr. Cunningham agreed to take part, and joined the event's advisory board.

"The idea is to get together and have a very interactive meeting, so that the early-stage companies get a showcase, and the industry and venture capital panels can discuss what they're looking for, where they see ophthalmology going, (and) how to contact them," Dr. Graves said.

Dr. Cunningham will moderate the venture capital panel, she added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.